Contact Us

5-Alpha Reductase Inhibitor
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

   * Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Parker Waichman LLP Headlines by Topic

5-Alpha Reductase Inhibitor

5-ARIs Get New Warnings for High-Grade Prostate Cancer in Canada

Mar 21, 2012
| Parker Waichman LLP
Health Canada has announced new warnings for 5-alpha reductase inhibitors, or 5-ARIs, regarding there association with an aggressive form of prostate...

Public Citizen Issues "Do Not Use" Recommendation for Avodart, Proscar

Oct 12, 2011
| Parker Waichman LLP
A leading consumer group is recommending that men with enlarged prostate consider alternatives to the drugs Avodart (dutasteride)  and Proscar...

Propecia, Other 5-ARIs Pose Risk of Erectile Dysfunction

Aug 22, 2011
| Parker Waichman LLP
Propecia and other drugs known as 5-alpha reductase inhibitors (5-ARIs) have been linked to erectile dysfunction, and other sexual problems in...

Health Canada Adds Male Breast Cancer Info to Propecia, Proscar Labels

Aug 5, 2011
| Parker Waichman LLP
The labels for Propecia and Proscar, as well as  generic forms of finasteride,  are being updated in Canada because of a possible...

FDA Orders New Prostate Cancer Warnings for Proscar, Avodart, Jalyn and Propecia

Jun 10, 2011
| Parker Waichman LLP
Proscar, Avodart, Jalyn and Propecia will all bear new warnings that they could increase the risk of high-grade prostate cancer, an aggressive form...

Page 1/1